PMA device
Contigen Bard Collagen Implant
Allergan, Inc. · Agent, Bulking, Injectable For Gastro-Urology Use (LNM, Class III) · First FDA decision Sep 21, 2006, newest Oct 2, 2009Overactive bladder and urinary incontinence
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
PMA pathway
Device trials
1
Naming "Contigen Bard Collagen"
MAUDE reports
31
Brand "Contigen Bard Collagen", since 2015
PubMed studies
3
Mentioning "Contigen Bard Collagen"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Contigen Bard Collagen Implant
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 2 of 2 decisions filed under this name.
- CONTIGEN BARD COLLAGEN IMPLANTPMA supplement
P900030-S011 · Decided Oct 2, 2009 · 213 days after receipt · Normal 180 Day Track No User Fee
Device type: AGENT, BULKING, INJECTABLE FOR GASTRO-UROLOGY USE (LNM) · GI, Urology & Nephrology
- CONTIGEN BARD COLLAGEN IMPLANTPMA supplement
P900030-S009 · Decided Sep 21, 2006 · 465 days after receipt · Normal 180 Day Track No User Fee
Device type: AGENT, BULKING, INJECTABLE FOR GASTRO-UROLOGY USE (LNM) · GI, Urology & Nephrology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Contigen Bard Collagen", any status and sponsor, newest update first.
Stanford UniversityAcademic, hospital or other
NCT01379378 · 0 participants · Start Oct 2011 · Primary completion Dec 2011
Device: Artificial urinary sphincter; InVance Sling and 2 more · For: Prostate Cancer
Sites: Stanford, California
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Contigen Bard Collagen", and for the whole product code for context.
This brand
31 reports: 0 malfunction, 31 injury, 0 death
Whole product code LNM
544 reports: 170 malfunction, 369 injury, 2 death
Newest reports for this brand
C.R. BARD, INC. (COVINGTON) -1018233
1018233-2019-02010 · Received Apr 17, 2019
Device type: Agent, Bulking, Injectable For Gastro-Urology Use (LNM)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Injury
C.R. BARD, INC. (COVINGTON) -1018233
1018233-2016-00577 · Received May 4, 2016
Device type: Agent, Bulking, Injectable For Gastro-Urology Use (LNM)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Micturition Urgency; Urinary Tract Infection; Injury
C.R. BARD, INC. (COVINGTON) -1018233
1018233-2016-00322 · Received Mar 22, 2016
Device type: Agent, Bulking, Injectable For Gastro-Urology Use (LNM)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Injury
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Contigen Bard Collagen"[tiab]. The summary above synthesizes these.
- Contigen Bard Collagen implant: the Japanese experience.
Yokoyama E · Int J Urol · 1995Clinical Trial, Multicenter Study
- Proper patient selection for Contigen Bard Collagen implant.
Stricker PD · Int J Urol · 1995
- Evaluation of antibody class in response to bovine collagen treatment in patients with urinary incontinence.
McClelland M, Delustro F · J Urol · 1996Clinical Trial, Multicenter Study
Other devices of this type
Also filed under product code LNM.
- Deflux Injectable GelPalette Life Sciences · PMA 2016
- Macroplastique ImplantsUroplasty, LLC · PMA 2023
- Solesta (Injectable Gel)Palette Life Sciences · PMA 2021
- Durasphere Injectable Bulking AgentCarbon Medical Technologies, Inc. · PMA 2026
- Coaptite Injectable ImplantMerz North America, Inc. · PMA 2024
- Bard Tegress Urethral ImplantC.R. Bard, Inc. · PMA 2006
- Enteryx Procedure KitBoston Scientific Corp · PMA 2005
- Durasphere ExpCarbon Medical Technologies, Inc. · PMA 2004
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.